A new study contributes to a growing body of evidence linking the cholesterol-lowering drugs called statins, such as Lipitor, with a higher risk of diabetes.
The Legal Examiner reported that in a study of U.K. medical records by Harvard School of Public Health, results showed “Statin therapy was associated with 14 percent increased risk of type 2 diabetes” and “[i]nitiating atorvastatin and simvastatin was associated with increased risk of type 2 diabetes.” These results fuse with a similar study in Canada that was published in the May 23 edition of the British Medical Journal that showed Lipitor stands out from other statins with a “22 percent increase in the risk of new onset diabetes.”
Despite the U.S. Food and Drug Administration’s approval of Lipitor in 1996, it was not until 2012 that the agency added warnings to the label advising that it may increase the risk of increased blood sugar levels and of being diagnosed with type 2 diabetes mellitus. The newspaper goes further to state that these warnings were a long time coming, and that Lipitor lawsuits are holding Pfizer accountable for failing to effectively provide such crucial diabetes-risk information. It implies that “not only were labeling changes insufficiently tardy, the product’s long-undetected defect apparently led to diabetes diagnoses.”
Because of this increased risk of new-onset diabetes, directly linked to Lipitor, lawsuits have been filed. Scientific evidence has been increasing rapidly for Lipitor patients, specifically women, who have been diagnosed with type-2 diabetes during or after taking the drug that will solidify injury claims contained in their Lipitor lawsuits. This science directly shows Lipitor as the primary statin for new-onset diabetes.
You should consult with a doctor before making any change in your medical care. If you or a loved one has developed type-2 diabetes during or after taking the drug, contact Lopez McHugh for a free consultation. At this time, Lopez McHugh is only accepting Lipitor cases involving women.
